Congestive Heart Failure in Copper-Deficient Mice

Abstract

Copper Deficiency (CuD) leads to hypertrophic cardiomyopathy in various experimental models. The morphological, electrophysiological, and molecular aspects of this hypertrophy have been under investigation for a long time. However the transition from compensated hypertrophy to decompensated heart failure has not been investigated in the study of CuD. We set out to investigate the contractile and hemodynamic parameters of the CuD mouse heart and to determine whether heart failure follows hypertrophy in the CuD heart. Dams of FVB mice were fed CuD or copper-adequate (CuA) diet starting from the third day post delivery and the weanling pups were fed the same diet for a total period of 5 weeks (pre- and postweanling). At week 4, the functional parameters of the heart were analyzed using a surgical technique for catheterizing the left ventricle. A significant decrease in left ventricle systolic pressure was observed with no significant change in heart rate, and more importantly contractility as measured by the maximal rate of left ventricular pressure rise (+dP/dt) and decline (−dP/dt) were significantly depressed in the CuD mice. However, left ventricle end diastolic pressure was elevated, and relaxation was impaired in the CuD animals; the duration of relaxation was prolonged. In addition to significant changes in the basal level of cardiac function, CuD hearts had a blunted response to the stimulation of the β-adrenergic agonist isoproterenol. Furthermore, morphological analysis revealed increased collagen accumulation in the CuD hearts along with lipid deposition. This study shows that CuD leads to systolic and diastolic dysfunction in association with histopathological changes, which are indices commonly used to diagnose congestive heart failure.

Get full access to this article

View all access options for this article.

References

Medeiros DM, Davidson J, Jenkins J. A unified perspective on copper deficiency and cardiomyopathy. Proc Soc Exp Biol Med 203 : 262–273, 1993.

Medeiros DM, Wildman REC. Newer findings on a unified perspective of copper restriction and cardiomyopathy. Proc Soc Exp Biol Med. 215 : 299–313, 1997.

Medeiros DM, Liao Z, Hamlin RL. Copper deficiency in a genetically hypertensive cardiomypathic rat: electrocardiogram, functional and ultrastructural aspects. J Nutr 121 : 1026–1034, 1991.

Kang YJ, Wu H, Saari JT. Alterations in hypertrophic gene expression by dietary copper restriction in mouse heart. Proc Soc Exp Biol Med 223 : 282–287, 2000.

Kang YJ, Zhou Z-X, Wu H, Wang G-W, Saari JT, Klein JB. Metallothionein inhibits myocardial apoptosis in copper-deficient mice: Role of atrial natriuretic peptide. Lab Invest 80 : 745–757, 2000.

Katz AM. Cardiomyopathy of overload. N Engl J Med 322 : 100–110, 1990.

Sasson Z, Rakowski H, Wigle ED. Hypertrophic cardiomyopathy. Cardiol Clin 6 : 233–288, 1988.

Towbin JA, Bowles NE. The failing heart. Nature 415 : 227–233, 2002.

Gillebert TC, Leite-Moreira AF, De Hart SG. Load dependent diastolic dysfunction in heart failure. Heart Failure Rev 5 : 345–355, 2000.

10.

Shimizu G, Hirota Y, Kawamura K. Empiric determination of the transition from concentric hypertrophy to congestive heart failure in essential hypertension. J Am Coll Cardiol 25 : 888–894, 1995.

11.

Armounds AA, Wu R, Juang G, Marban E, Tomaselli GF. Electrical and structural remodeling of the failing ventricle. Pharmacol Ther 92 : 213–230, 2001.

12.

Post SR, Hammond HK, Insel PA. β-Adrenergic receptors and receptor signaling in heart failure. Annu Rev Pharmacol Toxicol 39 : 343–360, 1999.

13.

Vatner DE, Asai K, Iwase M, Ishikawa Y, Shannon RP, Homcy CJ, Vatner SF. Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. Am J Cardiol 83 : 80H–85H, 1999.

14.

Brodde OE. β-adrenergic receptors in failing human myocardium. Basic Res Cardiol 91(Suppl. 2):35–40, 1996.

15.

Viestenz KE, Klevay LM. A randomized trial of copper therapy in rats with electrocardiographic abnormalities due to copper deficiency. Am J Clin Nutr 35 : 258–266, 1982.

16.

Kopp SJ, Klevay LM, Feliksik JM. Physiological and metabolic characterization of a cardiomyopathy by chronic copper deficiency. Heart Circ Physiol 14 : H855–H866, 1983.

17.

Lorenz JN, Robbins J. Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse. Am J Physiol 272 : H1137–H1146, 1997.

18.

Reeves PG, Nielson FH, Fahey GC. AIN-93 purified diets for laboratory rodents: Final report of the American Institute of Nutrition Ad Hoc Writing Committee on the reformulation of the AIN-76A rodent diet. J Nutr 123 : 1939–1951, 1993.

19.

Chu G, Li L, Sato Y, Harrer JM, Kadambi VJ, Hoit BD, Bers DM, Kranias EG. Pentametric assembly of phospholamban facilitates inhibition of cardiac function in vivo. J Biol Chem 273 : 33674–33680, 1998.

20.

Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 41 : 233–243, 1978.

21.

Covell JW, Chidsey CA, Braunwald E. Reduction of the cardiac response to Postganglionic sympathetic nerve stimulation in experimental heart failure. Circ Res 19 : 51–56, 1966.

22.

Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 : 819–823, 1984.

23.

Daly PA, Sole MJ. Myocardial catecholamines and the pathophysiology of heart failure. Circulation 82 : I35–I43, 1990.

24.

Morgan HE, Gordon EE, Kira Y, Chua BHL, Russo LA, Peterson CJ, McDermott PT, Watson PA. Biochemical mechanisms of cardiac hypertrophy. Annu Rev Physiol 49 : 533–543, 1987.

25.

Matter C, Nagel E, Stuber M, Boesiger P, Hess OM. Assessment of systolic and diastolic LV function by MR myocardial tagging. Basic Res Cardiol 91(Suppl. 2):23–28, 1996.

26.

Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med 325 : 1557–1564, 1991.

27.

Borg TK, Klevay LM, Gay RE, Siegel R, Bergin ME. Alteration of the connective tissue network of striated muscle in copper deficient rats. J Mol Cell Cardiol 17 : 1173–1183, 1985.

28.

Farquharson C, Duncan A, Robins SP. The effects of copper deficiency on the pyridinium crosslinks of mature collagen in the rat skeleton and cardiovascular system. Proc Soc Exp Biol Med 192 : 166–172, 1989.

29.

Chemla D, Coirault C, Hebert JL, Lecarpentier Y. Mechanisms of relaxation of the human heart. News Physiol Sci 15 : 78–83, 2000.

30.

Medeiros DM, Bagby D, Ovecka G, McCormick R. Myofibrillar, mitochondrial and valvular morphological alterations in cardiac hypertrophy among copper deficient rats. J Nutr 121 : 815–824, 1991.

31.

Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman A. M. Reduced β₁ receptor messenger RNA abundance in the failing human heart. J Clin Invest 92 : 2737–2745, 1993.

32.

Chen Y, Saari JT, Kang YJ. Copper deficiency increases metallothionein-I mRNA content selectively in rat liver. Nutr Biochem 6 : 572–576, 1995.

33.

Sunderman FW, Nomoto S. Measurement of human serum ceruloplasmin by Its p-phenylenediamine oxidase activity. Clin Chem 16 : 903–910, 1970.

34.

Spitz DR, Oberley LW. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal Biochem 179 : 8–18, 1989.

35.

Zar JH. Biostatistical Analysis. New Jersey: Prentice-Hall, p292, 1984.

36.

Heller LJ, Mohrman, DE, Pohaska, JR. Decreased passive stiffness of cardiac myocytes and cardiac tissue from copper-deficient rat hearts. Am J Physiol Heart Circ Physiol 278 : H1840–H1847, 2000.

37.

Prohaska JR, Heller LJ. Mechanical properties of the copper-deficient rat heart. J Nutr 112 : 2142–2150, 1982.